Claude Cowork 2.0 introduces direct computer control, a feature that allows users to assign tasks like managing files, navigating applications and drafting documents directly to the AI. According to ...

Marc Santos is a Guides Staff Writer from the Philippines with a BA in Communication Arts and over six years of experience in writing gaming news and guides. He plays just about everything, from ...

Cursor's latest Composer 2 model is based Moonshot AI's Kimi K2.5 model, confirmed the company. Cursor AI, the popular vibe coding platform, recently hit the headlines for releasing its Composer 2 ...

Khamosh Pathak is a freelance tech journalist with over 13 years of experience writing online. An accounting graduate, he turned his interest in writing and technology into a career. He holds a ...

Agentic AI is the latest buzzword in tech, with open-source AI agents like OpenClaw designed to autonomously carry out work tasks. Taiwanese officials say the technology could eventually be integrated ...

Many people believe closing their eyes sharpens hearing, but that is not always true. In noisy settings, participants struggled more to hear faint sounds with their eyes closed, while matching visuals ...

Call your agents. Or better yet, code them—using sentences as dead-simple as this one. AI assistants that can handle work and everyday personal tasks, all powered by brisk English-language commands ...

Steve Borthwick must throw off the shackles in Paris to inject some attacking energy into his far-too predictable side The inquest into England’s Six Nations campaign has already started and when that ...

MANILA, Philippines — To help people cope with rising costs and reduce the consumption of fuel, the Metropolitan Manila Development Authority has proposed a carpooling and shuttle service scheme to ...

Did our AI summary help? Fintech infrastructure startup Yubi is preparing for a market debut over the next 24 months after it turns profitable while it scales its international presence, founder and ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 Talapro-3 trial met its primary ...